These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 31101222)
1. Response letter to Dr. William's letter to the editor entitled "The CARVIVA HF trial - Is the devil in the detail?" published August 2018. Volterrani M; Cice G; Caminiti G; Vitale C; D'Isa S; Filardi PP; Acquistapace F; Marazzi G; Fini M; Rosano GMC Int J Cardiol; 2019 Aug; 288():114. PubMed ID: 31101222 [No Abstract] [Full Text] [Related]
2. The CARVIVA HF trial- Is the devil in the detail? Williams MR Int J Cardiol; 2019 Jan; 274():260. PubMed ID: 30078649 [No Abstract] [Full Text] [Related]
3. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Volterrani M; Cice G; Caminiti G; Vitale C; D'Isa S; Perrone Filardi P; Acquistapace F; Marazzi G; Fini M; Rosano GM Int J Cardiol; 2011 Sep; 151(2):218-24. PubMed ID: 21764469 [TBL] [Abstract][Full Text] [Related]
4. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807 [TBL] [Abstract][Full Text] [Related]
5. Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF. Cleland JG; Coletta AP; Castiello T; Clark AL Eur J Heart Fail; 2011 Oct; 13(10):1147-51. PubMed ID: 21896537 [TBL] [Abstract][Full Text] [Related]
6. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life. Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314 [TBL] [Abstract][Full Text] [Related]
7. Novel drugs for heart rate control in heart failure. Bielecka-Dabrowa A; von Haehling S; Rysz J; Banach M Heart Fail Rev; 2018 Jul; 23(4):517-525. PubMed ID: 29594814 [TBL] [Abstract][Full Text] [Related]
8. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925 [TBL] [Abstract][Full Text] [Related]
9. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. Fraga R; Franco FG; Roveda F; de Matos LN; Braga AM; Rondon MU; Rotta DR; Brum PC; Barretto AC; Middlekauff HR; Negrão CE Eur J Heart Fail; 2007; 9(6-7):630-6. PubMed ID: 17475552 [TBL] [Abstract][Full Text] [Related]
10. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653 [TBL] [Abstract][Full Text] [Related]
11. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure. Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326 [TBL] [Abstract][Full Text] [Related]
12. Different impact of carvedilol and transdermal scopolamine on cardiovascular performance of mild-moderate chronic heart failure patients: evidence of useful effects of scopolamine on tolerance to work load. De Vecchis R; Pucciarelli G; Setaro A; Nocerino L Minerva Cardioangiol; 2000 Nov; 48(11):393-410. PubMed ID: 11214431 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Guazzi M; Agostoni P; Matturri M; Pontone G; Guazzi MD Am Heart J; 1999 Sep; 138(3 Pt 1):460-7. PubMed ID: 10467196 [TBL] [Abstract][Full Text] [Related]
14. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L; Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495 [TBL] [Abstract][Full Text] [Related]
15. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. Gattis WA; O'Connor CM; Gallup DS; Hasselblad V; Gheorghiade M; J Am Coll Cardiol; 2004 May; 43(9):1534-41. PubMed ID: 15120808 [TBL] [Abstract][Full Text] [Related]
16. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure. Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with the beta-blocker carvedilol restores autonomic tone and responsiveness in patients with moderate heart failure. Malfatto G; Facchini M; Branzi G; Riva B; Sala L; Perego GB J Cardiovasc Pharmacol; 2003 Jul; 42(1):125-31. PubMed ID: 12827037 [TBL] [Abstract][Full Text] [Related]
18. Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern. Al-Nasser F; Yousufuddin M; Al-Nozha F; Anker SD; Coats AJ; Piepoli MF; Ponikowski PP Am J Cardiol; 2003 May; 91(10):1281-3. PubMed ID: 12745124 [No Abstract] [Full Text] [Related]
19. Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). Blanchet M; Ducharme A; Racine N; Rouleau JL; Tardif JC; Juneau M; Marquis J; Larivée L; Nigam A; Fortier A; White M Am J Cardiol; 2003 Sep; 92(5):548-53. PubMed ID: 12943875 [TBL] [Abstract][Full Text] [Related]
20. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial. Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]